AlphaFold AI redesigns gene-editing proteins to enhance safety, and biotech investors should pay attention

Team uses AlphaFold AI to redesign gene-editing proteins to make them safer

Researchers used AlphaFold to identify amino acid contacts in Cas9 responsible for off-target edits, then redesigned those regions to reduce errors in CRISPR-based gene therapies. Safer gene editing accelerates biotech commercialization and validates AI protein engineering as a foundation for clinical therapeutics, signaling increased M&A and investment in precision medicine.